Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: The ICE Study

Neurology

Volumn 72, Issue 15, 2009, Pages 1337-1344

  Merkies, I S J ^a   Bril, V ^b   Dalakas, M C ^c   Deng, C ^e   Donofrio, P ^d   Hanna, K ^e   Hartung, H P ^f   Hughes, R A C ^g   Latov, N ^h   van Doorn, P A ^a   Barroso, Fabio ⁱ   Nogués, Martin ⁱ   Rivero, Alberto ⁱ   Marchesoni, Cintia ^j   Pardal, Ana Maria ^j   Reisin, Ricardo ^j   Dubrovsky, Alberto ^k   Villa, Andres ^l   Chapman, Kristine ^m   Gibson, Gillian ^m   Adamova, Blanka ⁿ   Bednarik, Josef ⁿ   Vohanka, Stanislav ⁿ   Ehler, Eduard ^o   Haas, Judith ^p   Munch, Christoph ^q   Artamonov, Irina ^r   Drory, Vivian ^r   Groozman, Galina ^r   Buchman, Aron ^s   Chapman, Joab ^s   Uncini, Antonino ^t   Benedetti, Luana ^u   Ghiglione, Elisabetta ^u   Mancardi, Giovanni ^u   Narciso, Eleonora ^u   Schenone, Angelo ^u   Comi, Giancarlo ^v   Dacci, Patrizia ^v   Del Carro, Ubaldo ^v   Fazio, Raffaella ^v   Malaguti, Maria Chiara ^v   Riva, Nilo ^v   Ruiz Sandoval, Jose Luis ^w   Fryze, Waldemar ^x   Szczudlik, Andrzej ^y   Banach, Marta ^z   Selmaj, Krzysztof ^aa   Bogucki, Andrzej ^ab   Zielinska, Malgorzata ^ab   Stelmasiak, Zbigniew ^ac   Bartosik Psujek, Halina ^ad   Belniak, Ewa ^ad   Chyrchel, Urszula ^ad   Kaminski, Marek ^ad   Kostera Pruszczyk, Anna ^ae   Kwiecinski, Hubert ^ae   Apostolski, Slobodan ^af   Basta, Ivana ^af   Divac, Vesna ^af   Trikic, Rajko ^af   Oh, Shin ^ag   Caress, James ^ah   Cho, Sungho ^ai   Patwa, Huned ^aj   Tsao, Bryan ^ak   Thomas, Florian ^al   Trivedi, Jaya ^am   Wolfe, Gil ^am   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e Talecris Biotherapeutics Inc   (United States)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ FLENI   (Argentina)

^j HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^k HOSPITAL FRANCÉS   (Argentina)

^l HOSPITAL RAMOS MEJÍA   (Argentina)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^o Nemocnice Pardubice   (Czech Republic)

^p MARTIN LUTHER KRANKENHAUS   (Germany)

^q Neurologische Abteilung   (Germany)

^r TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^s SHEBA MEDICAL CENTER   (Israel)

^t Universita' degli Studi 'G D'Annunzio' di Chieti Nuovo Polo Didattico   (Italy)

^u UNIVERSITY OF GENOA   (Italy)

^v SAN RAFFAELE HOSPITAL   (Italy)

^w HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^x Wojewodzki Szpital   (Poland)

^y Clinical Neurology Centre   (Poland)

^z JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^aa N Barlicki University Hospital No 1 of Medical University of Lodz   (Poland)

^ab MEDICAL UNIVERSITY OF LODZ   (Poland)

^ac I Independent Clinical Hospital Lublin   (Poland)

^ad MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^ae MEDICAL UNIVERSITY OF WARSAW   (Poland)

^af UNIVERSITY OF BELGRADE   (Serbia)

^ag UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^ah WAKE FOREST BAPTIST HEALTH   (United States)

^ai STANFORD UNIVERSITY   (United States)

^aj YALE UNIVERSITY   (United States)

^ak LERNER RESEARCH INSTITUTE   (United States)

^al SAINT LOUIS UNIVERSITY   (United States)

^am UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNOGLOBULIN; OCTANOIC ACID; PLACEBO; IMMUNOGLOBULIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISABILITY; FUNCTIONAL STATUS; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MENTAL HEALTH; PHYSICAL ACTIVITY; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; SOCIAL INTERACTION; SOCIAL STATUS; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; DOUBLE BLIND PROCEDURE; PSYCHOLOGICAL ASPECT; SOCIAL BEHAVIOR;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MENTAL HEALTH; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; QUALITY OF LIFE; SOCIAL BEHAVIOR; YOUNG ADULT;

EID: 65349156859     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a0fd80     Document Type: Article

References (21)

1. Köller H, Kieseier BC, Jander S, Hartung H-P. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343-1356.
2. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46: 878-884.
3. Aaronson NK. Quality of life: What is it? How should it be measured? Oncology (Williston Park) 1988;2:64, 69-76.
4. International Classification of Functioning, Disability and Health (ICF). In: World Health Organization, 2001. Available at: www.who.int/classifications/ icf/en/. Accessed April 16, 2008.
5. Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999;66: 677-680.
6. Latov N. Diagnosis of CIDP. Neurology 2002;59(12 suppl 6):S2-S6.
7. Chiò A, Cocito D, Bottacchi E, et al. Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J Neurol Neurosurg Psychiatry 2007;78:1349-1353.
8. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993;56: 36-39.
9. van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990;40:209-212.
10. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 1996;119(pt 4):1067-1077.
11. Thompson N, Choudhary P, Hughes RA, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996;243: 280-285.
12. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-449.
13. Hughes R, Donofrio P, Bril V, et al; on behalf of the ICE Study Group. Intravenous immune globulin (10% caprylate/ chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE Study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-144.
14. McCrone P, Chisholm D, Knapp M, et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2003;10:687-694.
15. Merkies IS, Schmitz PI, van der Meche' FG, Samijn JP, van Doorn PA. Quality of life complements traditional outcome measures in immune-mediated polyneuropathies. Neurology 2002;59:84-91.
16. Padua L, Sabatelli M, Evoli A, Pazzaglia C, Tonali P. Intravenous immunoglobulin treatment in autoimmune neurological disorders: effects on quality of life. Hum Immunol 2005;66:417-421.
17. Hughes R, Bensa S, Willison H, et al; Inflammatory Neuropathy Cause and Treatment Group. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
18. Ware JE Jr, Kosinski M, Gandek B. SF-36® Health Survey: Manual and Interpretation Guide. Lincoln, RI: QualityMetric Inc.; 2000.
19. Merkies IS, Schmitz PI, van der Meche' FG, Samijn JP, van Doorn PA. Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve 2002;25:370-377.
20. Merkies IS, Schmitz PI, van der Meche' FG, van Doorn PA; for the Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Neurology 2000;54:943-949.
21. Merkies IS, Lauria G. 131st ENMC International Workshop: selection of outcome measures for peripheral neuropathy clinical trials 10-12 December 2004, Naarden, The Netherlands. Neuromuscul Disord 2006; 16:149-156.